I am downgrading Under Armour from Buy to Hold due to weak recent results, margin pressures, and a challenging North American turnaround. Q1 2026 showed some positives—higher gross margin, lower SG&A, and EMEA growth—but North America sales and guidance disappointed, driving the stock down 20%. Tariff headwinds and intense competition make a clear picture of a turnaround unlikely in the near te...
Under Armour has continued to report concerning revenue trends. Despite strength in EMEA, the brand turnaround is on uncertain grounds. Profitability has shown some progress, but tariffs now look to cause significant pressure from Q2 forward. Under Armour's tariff mitigation will only be reflected gradually. Under Amrour stock doesn't provide an attractive risk-to-reward entry point in my opini...
Under Armour, Inc. (NYSE:UAA ) Q1 2026 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants David E. Bergman - Chief Financial Officer Kevin A.
U.S. equities were higher in recent trading, with the Nasdaq on track to set another record closing high, as more companies posted solid earnings. The Dow and S&P 500 were higher as well.
Under Armour shares fell as much as 21% to $5.25 in early trading on Friday after the sportswear maker warned that sales would deteriorate further this quarter and that tariff-related costs for the fiscal year would be $100 million higher than expected.
Under Armour Inc (NYSE:UA) shares plunged more than 18% as its fiscal first quarter earnings fell short of expectations and weak guidance disappointed. For Q2, the athletic apparel brand expects revenue to decline 6% to 7% while gross margins are expected to decline 340 to 360 basis points, attributed to expected supply chain headwinds from tariffs.
Under Armour's fiscal second quarter outlook fell below Wall Street's expectations, and the company again did not provide full-year outlook.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.